Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate
Authors:
- Michael H. BaumannMBMichael H. Baumann
- Mario A. AyestasMAMario A. Ayestas
- Lawrence G. SharpeLSLawrence G. Sharpe
- David B. LewisDLDavid B. Lewis
- Kenner C. RiceKRKenner C. Rice
- Richard B. RothmanRRRichard B. Rothman
- 1 June 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 301 (3) , 1190-1197
Abstract
Methamphetamine abuse is a serious global health problem, and no effective treatments for methamphetamine dependence have been developed. In animals, the addictive properties of methamphetamine are mediated via release of dopamine (DA) from nerve terminals in mesolimbic reward circuits. At the molecular level, methamphetamine promotes DA release by a nonexocytotic diffusion-exchange process involving DA transporter (DAT) proteins. We have shown that blocking DAT activity with high-affinity DA uptake inhibitors, such as 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine (GBR12909), can substantially reduce amphetamine-induced DA release in vivo. In the present study, we examined the ability of a long-acting depot formulation of GBR12909 decanoate (GBR-decanoate) to influence neurochemical actions of methamphetamine in the nucleus accumbens of rats. Rats received single injections of GBR-decanoate (480 mg/kg i.m.) and were subjected to in vivo microdialysis testing 1 and 2 weeks later. Pretreatment with GBR-decanoate produced modest elevations in basal extracellular levels of DA, but not 5-hydroxytryptamine (5-HT), at both time points. GBR-decanoate nearly eliminated the DA-releasing ability of methamphetamine (0.3 and 1.0 mg/kg i.v.) for 2 weeks, whereas methamphetamine-induced 5-HT release was unaffected. Autoradiographic analysis revealed that GBR-decanoate caused long-term decreases in DAT binding in the brain. Our data suggest that GBR-decanoate, or similar agents, may be useful adjuncts in treating methamphetamine dependence. This therapeutic strategy would be especially useful for noncompliant patient populations.Keywords
This publication has 39 references indexed in Scilit:
- Evaluation of Phentermine and Fenfluramine, Alone and in Combination, in Normal, Healthy VolunteersNeuropsychopharmacology, 1996
- Reinforcing effects of certain serotonin-releasing amphetamine derivativesPharmacology Biochemistry and Behavior, 1996
- Effects of monoamine reuptake inhibitors on cocaine self-administration in ratsPharmacology Biochemistry and Behavior, 1995
- Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: II. Comparisons with other drugs and repeated administrations.Experimental and Clinical Psychopharmacology, 1995
- Visualizing Dopamine and Serotonin Transporters in the Human Brain with the Potent Cocaine Analogue [125I]RTI‐55: In Vitro Binding and Autoradiographic CharacterizationJournal of Neurochemistry, 1994
- Amphetamine: Effects on Catecholamine Systems and BehaviorAnnual Review of Pharmacology and Toxicology, 1993
- Cocaine Addiction: Psychology and NeurophysiologyScience, 1991
- A Tolerance Study of Single and Multiple Dosing of the Selective Dopamine Uptake Inhibitor GBR 12909 in Healthy SubjectsInternational Clinical Psychopharmacology, 1990
- High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug developmentLife Sciences, 1990
- Release and elimination of 14C‐fluphenazine enanthate and decanoate esters administered in sesame oil to dogsJournal of Pharmaceutical Sciences, 1976